Research Output Journal of Public Health and Medicine 3(1):29-35, 2024

ROJPHM ISSN: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

Regenerative Medicine and Organogenesis

Ugwu Okechukwu Paul-Chima, Alum Esther Ugo and Okon Michael Ben

Department of Publication and Extension Kampala International University Uganda

ABSTRACT

Regenerative medicine is a rapidly evolving field aimed at repairing, replacing, or regenerating human cells, tissues, and organs to restore normal function. This review explores the scope, historical background, and principles of organogenesis in regenerative medicine. It delves into the processes of embryonic development, cellular signaling, and differentiation essential for organ regeneration. The discussion includes various techniques such as stem cell therapy and tissue engineering, highlighting their applications in organ transplantation and wound healing. Despite the promise, numerous challenges remain, including the need for effective cell integration and overcoming ethical and logistical issues in organ donation.

Keywords: Regenerative Medicine, Organogenesis, Stem Cell Therapy, Tissue Engineering, Embryonic Development.

INTRODUCTION

Introduction to Regenerative Medicine: Regenerative medicine is an emerging field of medicine that seeks to replace or regenerate human cells, tissues, or organs in order to restore or establish normal function. Research in regenerative medicine is one of the most dynamic fields in contemporary biomedical research. In cardiology, it has sought to exploit the contributions of growth factors, such as the recognition of cardiomyogenic roles, and has evolved quickly into cell therapy using different cell sources. The objective is to replace lost cardiomyocytes with the maximum possible cardiac structure and function, valid for consideration in both chronic and acute ischemic heart diseases, using mainly autologous stem cells (bone marrow, peripheral blood, umbilical cord) with different recipient routes (intracoronary, intramyocardial, percutaneous intravenous) [1]. More recent studies include direct reprogramming of cardiac fibroblasts to induced pluripotent cardiomyocytes, which are an attractive option that does not require cell culture. Regulatory T cells, pluripotent cells, progenitor cells in the epicardium, endocardium, and many other sources are in recognition and it is even conceivable to engineer the myocardium with the desired characteristics. Each choice has its own peculiarities in the benefits and risks, and its use must be scaled individually, although the underlying concept of the "potential therapeutic value of regenerative medicine" is common. The organ consists of multiple tissues (epithelium, endothelium, mesenchyme, neuronal components), originating from different cell layers of discs, which play important roles in development, organogenesis, homeostasis, and for the final organizational and functional characteristics, and malformations during its course have a strong impact on behavior. Relevant studies have been developed for vital organs such as heart, liver, lungs, intestines, and kidneys, and many support systems for these organoids are being explored, including stem cell and extracellular matrix. Finally, the mechanistic study of myocardium reprogramming may contribute significantly to the feasibility of organoid formation, while direct reprogramming research leads to the same goal [2].

DEFINITION AND SCOPE

The human body is composed of about 100 trillion cells, all arising from the union of a sperm and an ovum that convey their genetic endowment to the fertilized egg. This, in turn, multiplies and differentiates to originate all the cells, tissues, organs, and structures required to make a new human being. Conventional biomedicine distinguishes two basic types of tissues: stable tissues that stay

untouched or regenerated throughout life, and continue to actively proliferate up to a certain degree when a portion is lost requiring repair, and permanent tissues, with high capacity for replication and differentiation. Regenerative medicine was born in humans with the first transplant of a heart in 1967 and from that point, various human organs and tissues have been transplanted [3]. The objective of regenerative medicine is to restore, maintain or enhance tissue or organ function, overcoming the problems of insufficient donor organs, immune rejection, secondary functional disorder by immunosuppressive agents, and ethical issues related to current transplantation therapy, by using cells, tissues and functional organs of the patients themselves to achieve self-regeneration of tissues and organs, considering the repair and replacement of tissues or defective organs. The separation of unique cells for cell therapy, the use of scaffolds for steady tissue optimization or to guide tissue regeneration, the use of biological agents (hormones, growth factors, cytokines, genes, etc.) to address tissue abnormalities, and the development of artificial organs, which duplicates the patient's organ function, are the innovative strategies that can be established with genetic factors (positioning or apoptosis). These strategies are only viable as long as the interconnected components work together reliably [4].

HISTORICAL BACKGROUND

The concept of replacing the missing or lost organs and tissues is probably as old as the existence of man. The Greek myth about the liver of Prometheus, growing back constantly after being eaten on a daily basis by an eagle, shows that humans have always dreamed about regenerating lost parts of a body. This concept is deeply rooted in the ancient dream of immortality that has accompanied man up to the present day. The initiative to repair damaged parts of the human body is found in the concept of transplantation and is also very old. Replacing the human body parts by using tissue of foreign origin has been perhaps one of the most daring initiatives to interfere with the human body structure [5]. Description of the murine mammary gland as a series of branched, walled-off, spherical structures composed of one or more epithelial cells was published by two French scientists, F. Déjerine-Klumpke and J. B. Déjerine, in the classic book Atlas d'Anatomie descriptive. This detailed description of the mammary gland evolution shows a similar process that, in the mouse, can be observed at the stages of its initial development, just after the anlage formation. Although both authors made several inferences based only on observations, there is a remarkable paragraph on page 458B of this paper where they wrote something rather unexpected. It is well known that if, in the adult, a part of a mammary gland were to be removed, there would be observed, after a variable period of time, a phenomenon of regeneration, characterized by the palpable increase in size of the organ [6].

PRINCIPLES OF ORGANOGENESIS

In order to apply the principles of organogenesis to regenerative medicine, one deals with these basic problems: induction of the required number of cells of a particular neural, blood or any other genotype at a given period of time of the first stages of embryo morphogenesis and cell differentiation into such or other functional specialization state. To solve these problems, one needs knowledge on the early differentiation of embryonic cells and regulation of this process in norm and pathology. The immediate task is to carry out differentiation of stem cells of other genotype and to solve the problems essential for body and organ individual development [7]. The obtained experimental results demonstrate the binding of the amplitude and direction of genetic regulatory programs of cell differentiation to the age of cells of the body or organ rudiment. For early embryo cells, available biological properties differ from superficial somatic cells of a grown body. Therefore, the choice and development of methods to solve the problems of regeneration require consideration of known embryonic cell particularities. Organogenesis and cell culture in tissue blocks are representative methods in the development of regenerative medicine [8].

EMBRYONIC DEVELOPMENT

The developing vertebrate starts off from a single cell derived from the fusion of a sperm and an egg. This cell divides into progressively more numerous cells, leading to the formation of a multicellular organism. The process by which this single-celled zygote goes through cellular division and determined changes in gene expression, changes in cell-cell adhesion, and cell shape modifications to pattern the body, form organs, differentiate cells, and finally create specialized tissues that compose the body plan is embryonic development. Using the axolotl as a model to study the development process and tissue regeneration, it generalizes principles that hold true throughout the entire animal kingdom. Central concepts are that a select number of cells, either plated in a dish or still in an organism, have the ability to give rise to every cell type in the adult body, known as stem cells [9]. Technically, the following properties differ between different types of stem cells and are affected by their environment. These are: Source (Biological Provenance), Differentiating Ability, Self-Renewal (Proliferative Potential), and Phenotype. Embryonic stem cells are pluripotent cells derived from the inner cell mass of the blastocyst

stage of a mouse or human, or even the prometum stage (4 cells) of non-human primate embryos. To derive ES cells from the blastocyst stage requires sacrifice. However, because of ethical and moral concerns, scientists have been investigating alternative sources for pluripotent cells. Adult stem cells are multipotent cells capable of self-renewal and with the potential to produce all the cell types of the tissue from which they originate [10, 11]. Embryonic stem cells are not subject to any developmental restraints; therefore, they are truly pluripotent. In contrast, adult stem cells are generally committed to generating cells of the tissue where stem cells reside, although on extremely rare occasions, adult stem cells are capable of producing cells of another tissue (otherwise non-stem cells after DNA damage or teratomas in vivo). Furthermore, adult stem cells in some tissues have relatively low proliferative potential compared to embryonic cells and are subject to telomere shortening over time, leading to replicative senescence. However, the lack of ancestral cell types in the adult stem cells may make them more suitable for transplantation therapy, since they do not form teratomas post-injection or post-implantation like ES cells [12]. The observation that some adult organs, like the skin, the blood/immune system, liver, shark eyes, and pancreas, can be completely regenerated in some vertebrates suggests that in these organs, adult stem cells or tissue-resident progenitor cells perform the same roles as embryonic stem cells during both embryonic development and regeneration. Characterization of these cells, their environment, and behavior is fundamental to the development of stem cell-based regenerative medicine applications. It should be underlined that the sources of these multipotent, tissue-renewable, and self-regenerating capacities of adult organs are associated with specific critical periods of development [13].

CELLULAR SIGNALING AND DIFFERENTIATION

The differentiation of primary hESCs into specialized somatic cells requires the manipulation of cell signaling pathways to mimic cell differentiation processes. This essential step is reproducible and facile since it replicates the normal processes of development and organogenesis. Several cellular growth factors and signaling modulators have been identified to direct the differentiation of hESCs into organ-specific progenitor cells. This strategy is usually based on the natural role of unique cell signaling pathways in promoting organ regeneration and development. The crucial determinants are the timing and spatial presentation of these factors throughout the stages of differentiation. Some signaling pathways acting in hESCs differentiation mimic those known to regulate embryology and fetal development. The transforming growth factor-b (TGF-b) superfamily, in particular the bone morphogenetic protein (BMP) members, can stimulate the direct in vitro differentiation of hESCs into multiple lineages. The BMP superfamily governs embryogenesis processes ranging from axis patterning to the formation of specific organs or tissues. This growth factor has specific activities in the embryonic development of the ectoderm, mesoderm, and endoderm. These growth factors are potent alternative choices for driving the specification of these three germ cell layers. The activated TGF-b superfamily members can initiate the commitment of four definitive lineages: the primitive endoderm into different endodermal cells, the visceral endoderm into gut effector cells, and the neuroectoderm into neural and glial effector cells. There are also branchpoints within each of these predominant lineages. Based on the recently established signaling relays and effector transcription factors in stem cell differentiation, BMP superfamily members are used to advance distinct early trophectodermal, karyotypically abnormal, embryonic endodermal, endodermal, and primitive ectodermal cells. It is challenging to synchronize the ability of BMP to address all the aspects of a multipotent cell fate decision in a reproducible manner. Another potential challenge for BMP usage in hESCs differentiation is the existence of precisely balanced microenvironments within specific regions of these three germ layers that currently require rigorous manipulation of other pertinent signaling pathways. Exploiting this complexity as an aided path to define the adult organ or tissue lineages will be of importance in human organogenesis research [15].

TECHNIQUES IN REGENERATIVE MEDICINE

TISSUE REGENERATION TECHNOLOGIES

There are significant differences in the approaches used for tissue regeneration between the two types of organs: those that develop after evagination and invagination - salivary glands, lungs, pancreas, liver, mammary glands, etc. - and those that are produced by branching morphogenesis and are called tubular organs. In the case of the developing lungs and pancreas, branching morphogenesis occurs through the formation of a ureteric bud and the duct of the posterior foregut. In adult organs of the pancreas, islets of Langerhans cells, in islet transplantation therapy, have been attracting therapeutic attention as tissues used for the treatment of diabetes. Other approaches use a variety of cells such as alpha or beta cells and deliver them by injection or ex vivo manipulation. In the case of the liver, research models pursue the creation of an artifi-cial liver that utilizes a bioartificial liver system, liver assist devices, hepatocyte

transplantation, or a liver organoid. In some cases, biological or synthetic artificial organs can be transplanted or implanted into a patient [16].

STEM CELL THERAPY

Various types of cells have been utilized for various therapeutic applications in the field of organ regeneration. The most widely known cells include hematopoietic stem cells, mesenchymal stem cells, and induced pluripotent stem (iPS) cells. These cells are commonly used not only for research but also for clinical treatments. Each has its own characteristics and shows different functions and effects. Below, their functions and effects are described to show how to utilize them in the field of regenerative medicine [17]. Experimental data indicate that using cells such as bone marrow-derived mononuclear cells, bone marrow-derived mesenchymal stem cells (MSCs), adipose-derived MSCs, and endothelial progenitor cells can affect the infarcted myocardium, ultimately resulting in the generation of new cardiac cells and increasing angiogenic activity [18]. Bone marrow mesenchymal stem cells possess the potential to differentiate into cardiomyocytes. However, because it is difficult for the mesenchymal stem cells to differentiate into cardiomyocytes, other factors such as IGF-1, microRNA, microvesicles from the plasma, and platelets recruited by the mesenchymal stem cells contribute to improved heart function. Furthermore, embryonic stem cells and iPS cells that are potential donors for the regeneration of injured organs, especially vital organs, have the capability of extensive self-renewal and multidirectional differentiation. More recently, cardiomyocytes and other differentiated cells necessary for the heart or other organs have been produced. However, expression of the target gene or the provision of a suitable environmental stimulus to enable in-vivo tissue integration with the host organ of transplanted cells are challenges to their use [19].

TISSUE ENGINEERING

Cells are naturally found in a complex three-dimensional (3D) microenvironment, within an extracellular matrix as well as in a fluid containing numerous paracrine signals. This unique ecosystem, precisely defining cell spatial organization and intercellular communication, is referred to as the native tissue niche. Tissue engineering is the science of recreating this environment ex vivo, to produce 3D structures composed of one or several cell types, culture media, and scaffold materials of natural or synthetic origin. In this context, a scaffold is a three-dimensional substrate used to promote spatial distribution of cells and subsequent tissue organization during in vitro culture or after in vivo positioning. Such scaffolds are designed to, at least partially, mimic the natural ECM composition and physical properties of different tissues, including mechanical protection and terminal differentiation signals. Data obtained by diverse research groups have shown that the combination of modulus and topography of polymeric materials plays a fundamental role during stem cell adhesion and proliferation, and in the induction of lineage-specific differentiation [20]. Other than the stem cells, the synthesis and production of the natural or biological material often employed in the construction of the scaffold are other key factors in the field of tissue engineering, otherwise known as the technology of smart degradation products such as extracellular matrix (ECM), decellularized organs, and tissue scaffolds. Currently, the conventional techniques of producing a complex structure from ECM are limited to mainly labor-intensive methods or frozen decellularized tissues. These methods give small-scale products with uncertain cell survivability, even though decellularized organs maintain some original physical and mechanical properties. Extracellular matrices have proved to be useful materials for tissue reconstruction due to their good biocompatibility, bioactivity, and remodeling capacity, in part owing to the complex maintenance of the native ECM, optimized structure, and surface properties like micro and nanotopography [21].

APPLICATIONS OF REGENERATIVE MEDICINE

The ability of mesenchymal stem cells to give rise to a large number of cell types and its circumvention of ethical controversies related to hESC has inspired widespread research for therapeutic applications. A great challenge is to develop methods for delivering large numbers of cells to damaged organs and tissues to expedite their repair. Also, expanding cells in vitro and separating correct cell types is another challenge. Organ printing, converting invented bioprinting used in the field of rapid prototyping, uses printing, scanning, and computer-aided design technologies to place cells, growth factors, and biomaterials on a matrix in a certain type of organ. Although it seems to be easy, it still remains technologically sophisticated with challenges to be conquered. Although progress continues to be made concerning the perfection of printing pattern design with order, variety, and concentration of complex cells, bioactive components, and biomaterials, many difficulties still persist [22].

ORGAN TRANSPLANTATION

Most organ transplants are very challenging operations that require not only transplanting the targeted organ, but also carefully routing all of the arteries, veins, and other connections necessary to maintain the

organ's blood supply and drainage. The specialized surgical expertise required to perform these operations was not developed until after the immunosuppressive drugs became available because the rapidly removed immune response was an absolute requirement for the procedures to succeed. Now, the major problems with organ transplantation result from the need to suppress the immune system of the recipient to prevent them from rejecting the transplanted organ. Immunosuppressive drugs also increase the probability of the patient developing life-threatening infections and cancers. Other problems result from the currently limited availability of healthy human organs. Thousands of patients waiting to receive organ transplants die every year [23]. About half of the transplantable organs currently used come from healthy people who were brain dead as a result of car accidents, violent crimes, or other tragic accidents. Organ donation is an important way that the organs from these people can allow part of them to continue to live. However, the number of these types of donors is substantially smaller than the estimated 55,000 people a year who need organs. Stimulating more healthy donors would still not enable organ procurement to keep up with the demand because many diagnostic tools and medications have been developed that save or extend the lives of people with accident-related injuries that were fatal in earlier years. For example, only about 1% of deaths in the United States occur in a manner that makes them suitable for organ donation. The other transplantable organs come from overall healthy individuals who were alive and heart beating but who were declared medically dead because of other severe injuries. In 2004, over 37% of the deceased donors who provided organs were over 50 years old. Increases in the number of healthy people who are able to become donors, and who give consent for their organs to be used to help other people, will become less likely over time as advances in medical diagnosis and treatment lead to fewer accident-related deaths, and as the number of injured elderly individuals continues to rise [24].

WOUND HEALING AND SKIN REGENERATION

The need to develop tools and methods that can restore skin function and structure, benefit the healing process, and reduce scarring is present both in chronic wounds and in burns. This need has resulted in a surge of interest in the use of regenerative medicine, including stem cells, mesenchymal cells, growth factors, and scaffolds. Although typically complex, the skin wound healing process parallels embryogenesis in some ways, and consequently, this makes skin an attractive option when the goal of regenerative medicine is to restore tissue architecture and function, hence promoting the ultimate goal of regeneration. In general, the skin renews from the action of resident stem cells that are located in certain skin compartments. When the number of stem cells falls, genetically determined proliferating cells located in the basal layer fill the gap, becoming stem cells and forming the structure of the epidermis. Similarly, mesenchymal stem cells along the dermis allow communication between the epidermis and underlying structures [25].

CHALLENGES AND FUTURE DIRECTIONS

Issues discussed in this review document some of the hurdles that scientific and medical communities have to surmount to develop practical and effective regenerative medicine strategies. The complexity of cell therapies and tissue engineering approaches (including the crosstalk of cells at pivotal stages like differentiation or organogenesis, the role of stem cells in cellular therapies, etc.) suggests that it will take many years to translate current in vitro advances in regenerative biology to stem cell-/progenitor cell-based therapies. Positive results in clinical trials currently being developed should open short-term perspectives for the optimization of several currently drastic and often damaging and/or allogeneic cell therapy to attain less invasive and more physiologic reconstitutive strategies. Moreover, addressing the shortage of donor organs available for allogeneic transplantation in a decade would be facilitated by regenerative biological solutions [26]. Challenges include mimicking as close as possible stem cell niches which maintain self-renewal capacity upon controlled proliferation and inductive/instructive changes in cell's fate and function; obtaining effective homing, engraftment, and cell action at the right location in vivo; and ensuring both biosecurity for patients treated with innovative regenerative procedures and the quality of required cell populations. Some of the challenges have already been experimentally resolved, providing future promising results for cell-based therapies. However, there are also numerous poorly understood natural cell processes which could subsequently, conversely become critical for maintaining "stable" cell phenotypes and avoiding secondary de/differentiation of some of the cells used. Commercialization of some of the therapies is also striking back due to the proprietary nature of several environmental factors of preclinical and, for some of them, commercial stem cell culture media [27].

CONCLUSION

Regenerative medicine holds immense potential for revolutionizing the treatment of damaged tissues and organs, addressing the limitations of traditional transplantation and overcoming the shortage of donor

organs. Through advancements in stem cell therapy, tissue engineering, and an improved understanding of cellular signaling and differentiation, the field is steadily progressing towards clinical applications. However, significant challenges remain, including ensuring the safety and efficacy of these therapies, ethical considerations, and technological hurdles. Future research and collaboration across scientific and medical disciplines are essential to fully realize the potential of regenerative medicine in improving human health and longevity.

REFERENCES

1. Tavakoli S, Ghaderi Jafarbeigloo HR, Shariati A, Jahangiryan A, Jadidi F, Jadidi Kouhbanani MA, Hassanzadeh A, Zamani M, Javidi K, Naimi A. Mesenchymal stromal cells; a new horizon in regenerative medicine. Journal of cellular physiology. 2020 Dec;235(12):9185-210. [HTML]
2. Adams E, McCloy R, Jordan A, Falconer K, Dykes IM. Direct reprogramming of cardiac fibroblasts to repair the injured heart. Journal of cardiovascular development and disease. 2021 Jun 22;8(7):72. mdpi.com
3. Baluška F, Miller Jr WB, Reber AS. Biomolecular basis of cellular consciousness via subcellular nanobrains. International Journal of Molecular Sciences. 2021 Mar 3;22(5):2545. mdpi.com
4. Aiman AR, Vigneswari S, Amran NA, Murugaiyah V, Amirul AA, Ramakrishna S. Advancing Regenerative Medicine Through the Development of Scaffold, Cell Biology, Biomaterials and Strategies of Smart Material. Regenerative Engineering and Translational Medicine. 2022:1-23. [HTML]
5. Niklason LE, Lawson JH. Bioengineered human blood vessels. Science. 2020. [HTML]
6. Rauner G, Kuperwasser C. Microenvironmental control of cell fate decisions in mammary gland development and cancer. Developmental Cell. 2021. cell.com
7. Veenvliet JV, Lenne PF, Turner DA, Nachman I, Trivedi V. Sculpting with stem cells: how models of embryo development take shape. Development. 2021 Dec 15;148(24):dev192914. biologists.com
8. Zhu M, Zernicka-Goetz M. Principles of self-organization of the mammalian embryo. Cell. 2020. cell.com
9. Estermann MA, Smith CA. Applying single-cell analysis to gonadogenesis and DSDs (Disorders/Differences of Sex Development). International Journal of Molecular Sciences. 2020. mdpi.com
10. Fléchon JE. What are ES cells?. Transgenic Animals. 2022. [HTML]
11. Yu L, Wei Y, Duan J, Schmitz DA, Sakurai M, Wang L, Wang K, Zhao S, Hon GC, Wu J. Blastocyst-like structures generated from human pluripotent stem cells. Nature. 2021 Mar 25;591(7851):620-6. researchgate.net
12. Priester C, MacDonald A, Dhar M, Bow A. Examining the characteristics and applications of mesenchymal, induced pluripotent, and embryonic stem cells for tissue engineering approaches across the germ …. Pharmaceuticals. 2020. mdpi.com
13. Ferrario C, Sugni M, Somorjai IM, Ballarin L. Beyond adult stem cells: dedifferentiation as a unifying mechanism underlying regeneration in invertebrate deuterostomes. Frontiers in Cell and Developmental Biology. 2020 Oct 20;8:587320. frontiersin.org
14. Sun L, Fu X, Ma G, Hutchins AP. Chromatin and epigenetic rearrangements in embryonic stem cell fate transitions. Frontiers in cell and developmental biology. 2021 Feb 18;9:637309. frontiersin.org
15. Shu DY, Lovicu FJ. Insights into bone morphogenetic protein—(BMP-) signaling in ocular lens biology and pathology. Cells. 2021. mdpi.com
16. Lang C, Conrad L, Iber D. Organ-specific branching morphogenesis. Frontiers in Cell and Developmental Biology. 2021 Jun 7;9:671402. frontiersin.org
17. Dupuis V, Oltra E. Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells. World Journal of Stem Cells. 2021. nih.gov
18. Zhang R, Yu J, Zhang N, Li W, Wang J, Cai G, Chen Y, Yang Y, Liu Z. Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial. Stem cell research & therapy. 2021 Dec;12:1-4. springer.com
19. Li J, Lv Y, Wang H, Liu Y et al. Cardiomyocyte-like cell differentiation by FGF-2 transfection and induction of rat bone marrow mesenchymal stem cells. Tissue and Cell. 2021. [HTML]
20. Hu W, Shi J, Lv W, Jia X, Ariga K. Regulation of stem cell fate and function by using bioactive materials with nanoarchitectonics for regenerative medicine. Science and Technology of Advanced Materials. 2022 Dec 31;23(1):393-412. tandfonline.com

21. Joyce K, Fabra GT, Bozkurt Y, Pandit A. Bioactive potential of natural biomaterials: Identification, retention and assessment of biological properties. Signal transduction and targeted therapy. 2021 Mar 19;6(1):122. nature.com
22. Rodríguez-Fuentes DE, Fernández-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldaña HA. Mesenchymal stem cells current clinical applications: a systematic review. Archives of medical research. 2021 Jan 1;52(1):93-101. sciencedirect.com
23. Lascaris B, Thorne AM, Lisman T, Nijsten MW, Porte RJ, de Meijer VE. Long-term normothermic machine preservation of human livers: what is needed to succeed?. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2022 Feb 1;322(2):G183-200. physiology.org
24. Park C, Jones MM, Kaplan S, Koller FL, Wilder JM, Boulware LE, McElroy LM. A scoping review of inequities in access to organ transplant in the United States. International journal for equity in health. 2022 Feb 12;21(1):22. springer.com
25. Narauskaitė D, Vydmantaitė G, Rusteikaitė J, Sampath R, Rudaitytė A, Stašytė G, Aparicio Calvente MI, Jekabsone A. Extracellular vesicles in skin wound healing. Pharmaceuticals. 2021 Aug 18;14(8):811. mdpi.com
26. Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nature Reviews Drug Discovery. 2022 Sep;21(9):655-75. nature.com
27. Ramos-Rodriguez DH, MacNeil S, Claeyssens F, Asencio IO. The use of microfabrication techniques for the design and manufacture of artificial stem cell microenvironments for tissue regeneration. Bioengineering. 2021 Apr 23;8(5):50. mdpi.com

CITATION: Ugwu Okechukwu Paul-Chima, Alum Esther Ugo and Okon Michael Ben. (2024). Regenerative Medicine and Organogenesis. Research Output Journal of Public Health and Medicine 3(1):29-35